These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
456 related articles for article (PubMed ID: 15350712)
1. Use of palivizumab to control an outbreak of syncytial respiratory virus in a neonatal intensive care unit. Abadesso C; Almeida HI; Virella D; Carreiro MH; Machado MC J Hosp Infect; 2004 Sep; 58(1):38-41. PubMed ID: 15350712 [TBL] [Abstract][Full Text] [Related]
2. Experience with the use of palivizumab together with infection control measures to prevent respiratory syncytial virus outbreaks in neonatal intensive care units. Kurz H; Herbich K; Janata O; Sterniste W; Bauer K J Hosp Infect; 2008 Nov; 70(3):246-52. PubMed ID: 18799241 [TBL] [Abstract][Full Text] [Related]
3. The use of palivizumab monoclonal antibody to control an outbreak of respiratory syncytial virus infection in a special care baby unit. Cox RA; Rao P; Brandon-Cox C J Hosp Infect; 2001 Jul; 48(3):186-92. PubMed ID: 11439005 [TBL] [Abstract][Full Text] [Related]
4. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173 [TBL] [Abstract][Full Text] [Related]
6. Readmission with respiratory syncytial virus (RSV) infection among graduates from a neonatal intensive care unit. McCormick J; Tubman R Pediatr Pulmonol; 2002 Oct; 34(4):262-6. PubMed ID: 12205567 [TBL] [Abstract][Full Text] [Related]
7. Palivizumab prophylaxis during nosocomial outbreaks of respiratory syncytial virus in a neonatal intensive care unit: predicting effectiveness with an artificial neural network model. Saadah LM; Chedid FD; Sohail MR; Nazzal YM; Al Kaabi MR; Rahmani AY Pharmacotherapy; 2014 Mar; 34(3):251-9. PubMed ID: 23897635 [TBL] [Abstract][Full Text] [Related]
8. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile? Hashmi NA; Cosgrove JF; MacMahon P Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917 [TBL] [Abstract][Full Text] [Related]
9. Use of palivizumab and infection control measures to control an outbreak of respiratory syncytial virus in a neonatal intensive care unit confirmed by real-time polymerase chain reaction. O'Connell K; Boo TW; Keady D; Niriain U; O'Donovan D; Commane M; Faherty C; Cormican M J Hosp Infect; 2011 Apr; 77(4):338-42. PubMed ID: 21330007 [TBL] [Abstract][Full Text] [Related]
10. Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with Palivizumab as RSV prophylaxis. Lacaze-Masmonteil T; Rozé JC; Fauroux B; Pediatr Pulmonol; 2002 Sep; 34(3):181-8. PubMed ID: 12203846 [TBL] [Abstract][Full Text] [Related]
11. Use of palivizumab with other infection control measures to control respiratory syncytial virus outbreaks in neonatal care units. Hammoud MS; Al-Taiar A; Raina A; Elsori D; Al-Qabandi S; Al-Essa M J Trop Pediatr; 2016 Oct; 62(5):409-14. PubMed ID: 27118823 [TBL] [Abstract][Full Text] [Related]
12. RSV outbreak in a paediatric intensive care unit. Thorburn K; Kerr S; Taylor N; van Saene HK J Hosp Infect; 2004 Jul; 57(3):194-201. PubMed ID: 15236847 [TBL] [Abstract][Full Text] [Related]
13. [Outbreak of respiratory syncytial virus at a neonatal intensive care unit in Mexico City]. Murguía-de Sierra T; Casasola-Flores J; Rosales-Urbán S; Nava-Ibarra V; Navarrete-Navarro S Bol Med Hosp Infant Mex; 1993 Oct; 50(10):709-16. PubMed ID: 8216868 [TBL] [Abstract][Full Text] [Related]
14. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage. Romero JR Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452 [TBL] [Abstract][Full Text] [Related]
15. Palivizumab use in very premature infants in the neonatal intensive care unit. Wu SY; Bonaparte J; Pyati S Pediatrics; 2004 Nov; 114(5):e554-6. PubMed ID: 15520088 [TBL] [Abstract][Full Text] [Related]
16. Palivizumab prophylaxis and hospitalization for respiratory syncytial virus disease in the Stockholm infant population, 1999 through 2002. Henckel E; Luthander J; Berggren E; Kapadia H; Naver L; Norman M; Bennet R; Eriksson M Pediatr Infect Dis J; 2004 Jan; 23(1):27-31. PubMed ID: 14743042 [TBL] [Abstract][Full Text] [Related]
17. [Chemoprophylaxis with palivizumab in Andalusia (Spain). Results of the 2000-2001 respiratory syncytial virus epidemic]. Grupo de Hospitales Benazuza An Esp Pediatr; 2002 Apr; 56(4):293-7. PubMed ID: 11927095 [TBL] [Abstract][Full Text] [Related]
18. Beyond randomized controlled trials: a "real life" experience of respiratory syncytial virus infection prevention in infancy with and without palivizumab. Mitchell I; Tough S; Gillis L; Majaesic C Pediatr Pulmonol; 2006 Dec; 41(12):1167-74. PubMed ID: 17058279 [TBL] [Abstract][Full Text] [Related]
19. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis. Heikkinen T; Valkonen H; Lehtonen L; Vainionpää R; Ruuskanen O Arch Dis Child Fetal Neonatal Ed; 2005 Jan; 90(1):F64-8. PubMed ID: 15613580 [TBL] [Abstract][Full Text] [Related]